Welcome to our dedicated page for Bausch & Lomb SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bausch & Lomb's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bausch & Lomb's regulatory disclosures and financial reporting.
ROBERTSON RUSSEL C reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp director Russel C. Robertson received an equity award of 1,611 common shares on April 30, 2026. The filing describes these as restricted share units, each representing a contingent right to receive one common share of Bausch & Lomb.
After this grant, Robertson directly holds 78,418 common shares. This is a compensation-related grant, not an open-market purchase, and reflects additional alignment of the director’s interests with common shareholders through stock-based awards.
Bausch & Lomb Corp director John Paulson received an equity grant. He acquired 1,375 restricted share units, each representing a contingent right to receive one common share of Bausch & Lomb, at a reference price of $15.90 per share.
Following this grant, Paulson directly holds 73,981 common shares. This is a compensation-related award reported as an acquisition, not an open-market purchase or sale.
Bausch & Lomb Corp director Steven H. Collis received a grant of restricted share units in the company. On this award date, he acquired 1,415 restricted share units, each representing a contingent right to receive one common share of Bausch & Lomb. Following this award, his directly held common share-equivalent position reported in this filing is 26,161 shares.
Bausch & Lomb Corp director Alfonso Eduardo reported an acquisition of 1,375 common shares on April 30, 2026 through a grant of restricted share units. Each unit represents a contingent right to receive one common share at a reference price of $15.90 per share.
After this compensation-related award, Eduardo directly holds 15,230 common shares. This filing reflects an equity grant rather than an open-market purchase or sale, and does not involve any derivative exercises.
Bausch + Lomb Corporation reported first-quarter 2026 results showing higher sales but a continued net loss. Revenues reached $1,244 million, up from $1,137 million a year earlier, driven by product sales across its Vision Care, Pharmaceuticals and Surgical eye-health segments.
Operating income improved to $33 million from an operating loss of $83 million, and the net loss attributable to the company narrowed to $71 million from $212 million, or $0.20 per share versus $0.60. Cash from operating activities was $32 million compared with a $25 million use of cash in the prior-year quarter. As of March 31, 2026, total assets were $13,780 million, long-term debt and other financial liabilities (net of issuance costs) were about $5,039 million, and cash and cash equivalents were $268 million. Bausch Health Companies Inc. continued to own roughly 87% of Bausch + Lomb’s common shares, with 356,536,358 common shares outstanding as of April 22, 2026.
Bausch + Lomb reported solid first-quarter 2026 growth and raised its full-year outlook. Revenue reached $1.244 billion, up 9% from the first quarter of 2025, or 6% on a constant currency basis, driven by all three segments.
Vision Care revenue grew to $711 million, Surgical to $228 million, and Pharmaceuticals to $305 million, with Pharmaceuticals up 14% and led by strong MIEBO and XIIDRA sales. Operating results improved markedly, shifting from an operating loss of $83 million to operating income of $33 million.
The company still posted a GAAP net loss of $71 million, but adjusted net income was $19 million and cash flow from operations turned positive at $32 million. Adjusted EBITDA rose to $189 million, or $200 million excluding acquired IPR&D, prompting higher 2026 revenue and adjusted EBITDA guidance.
Bausch & Lomb Corp President, GPIC Andrew J. Stewart reported a routine tax-withholding share disposition. On the vesting of restricted share units, 4,216 common shares were withheld at $15.82 per share to cover tax obligations. After this non-market transaction, he holds 86,433 common shares directly.
Bausch & Lomb Corp executive Robert D. Bailey, EVP & Chief Legal Officer, reported a routine tax-related share disposition. On this Form 4, 15,806 common shares were withheld at $15.82 per share to cover tax withholding obligations from vesting restricted share units. Following this withholding, Bailey directly holds 230,684 common shares, indicating this was not an open-market sale but a standard mechanism to satisfy taxes due at vesting.
Bausch + Lomb Corporation is asking shareholders to vote at its virtual 2026 Annual Meeting on May 20, 2026. Investors will elect ten directors, hold an advisory vote on executive pay, and decide on amending the 2022 Omnibus Incentive Plan to add 25,000,000 common shares for equity awards.
Shareholders will also vote on appointing PricewaterhouseCoopers LLP as auditor and receive the 2025 audited financial statements. The proxy highlights a largely independent, skills‑based board, detailed committee structure, strong ESG oversight, and extensive sustainability initiatives, including a 2050 net zero goal and expanded recycling and decarbonization programs.